Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Auremolimab
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Incyte Corporation
Deal Size : $1,430.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize auremolimab (VM6, an anti-IL-15Rβ monoclonal antibody) for all uses, including in vitiligo and other autoimmune and inflammatory ...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $70.0 million
October 03, 2022
Lead Product(s) : Auremolimab
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Incyte Corporation
Deal Size : $1,430.0 million
Deal Type : Acquisition
Reset All
